Seminars in Diagnostic Pathology
Volume 27, Issue 1 , Pages 91-96 , February 2010

Breast pathology: beyond morphology

  • Peter T. Simpson, PhD

      Affiliations

    • University of Queensland Centre for Clinical Research, The Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
    • ,
  • Jorge S. Reis-Filho, MD, PhD, FRCPath

      Affiliations

    • The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    • Corresponding Author InformationAddress reprint requests and correspondence: Jorge S. Reis-Filho, MD, PhD, FRCPath, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Rd, London SW3 6JB UK
    • ,
  • Sunil R. Lakhani, BSc, MBBS, FRCPath, FRCPA

      Affiliations

    • University of Queensland Centre for Clinical Research, The Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
    • School of Medicine, The Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
    • Pathology Queensland, The Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
    • Corresponding Author InformationSunil R. Lakhani, BSc, MBBS, FRCPath, FRCPA, UQ Centre for Clinical Research, Level 6 Building 71/918, University of Queensland, The Royal Brisbane and Women's Hospital, Herston 4029, Brisbane, QLD, Australia

References 

  1. Ellis IO, Galea M, Broughton N, et al. Pathological prognostic factors in breast cancer (II. Histological type. Relationship with survival in a large study with long-term follow-up). Histopathology. 1992;20:479–489
  2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer (I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up). Histopathology. 1991;19:403–410
  3. Oldenhuis CN, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44:946–953
  4. Azzopardi JG. Problems in Breast Pathology. London, United Kingdom: W B Saunders Company LTD; 1979;
  5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  6. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874
  7. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retrospective of the last decade. J Pathol. 2009;220:263–280
  8. Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2001;195:41–52
  9. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol. 1999;187:396–402
  10. Lakhani SR. Is there a benign to malignant progression?. Endocr Relat Cancer. 1997;4:93–104
  11. Nishizaki T, Chew K, Chu L, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer. 1997;74:513–517
  12. Pollack JR, Perou CM, Alizadeh AA, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999;23:41–46
  13. Reis-Filho JS, Simpson PT, Gale T, et al. The molecular genetics of breast cancer: The contribution of comparative genomic hybridization. Pathol Res Pract. 2005;201:713–725
  14. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol. 2005;205:248–254
  15. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10:529–541
  16. Natrajan R, Lambros MB, Geyer FC, et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. Genes Chromosomes Cancer. 2009;48:351–365
  17. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res. 2009;15:2711–2722
  18. Natrajan R, Weigelt B, Mackay A, et al: An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (in press)
  19. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15:441–451
  20. Buerger H, Otterbach F, Simon R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999;189:521–526
  21. Buerger H, Simon R, Schafer KL, et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol. 2000;53:118–121
  22. Roylance R, Gorman P, Papior T, et al. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene. 2006;25:6544–6553
  23. Stratton MR, Collins N, Lakhani SR, et al. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol. 1995;175:195–201
  24. Roylance R, Gorman P, Hanby A, et al. Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol. 2002;196:32–36
  25. Cleton-Jansen AM, Buerger H, Haar N, et al. Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer. 2004;41:109–116
  26. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: An aggressive tumor showing apocrine differentiation. Hum Pathol. 1992;23:655–662
  27. Middleton LP, Palacios DM, Bryant BR, et al. Pleomorphic lobular carcinoma: Morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol. 2000;24:1650–1656
  28. Palacios J, Sarrio D, Garcia-Macias MC, et al. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod Pathol. 2003;16:674–678
  29. Simpson PT, Gale T, Fulford LG, et al. The diagnosis and management of pre-invasive breast disease: Pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003;5:258–262
  30. Sneige N, Wang J, Baker BA, et al. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: A report of 24 cases. Mod Pathol. 2002;15:1044–1050
  31. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol. 1992;23:1167–1171
  32. Orvieto E, Maiorano E, Bottiglieri L, et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: Results of an analysis of 530 cases from a Single Institution. Cancer. 2008;113:1511–1520
  33. Buchanan CL, Flynn LW, Murray MP, et al. Is pleomorphic lobular carcinoma really a distinct clinical entity?. J Surg Oncol. 2008;98:314–317
  34. Simpson P, Reis-Filho JS, Lambros M, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: Evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol. 2008;215:231–244
  35. Marchio C, Iravani M, Natrajan R, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol. 2008;215:398–410
  36. Marchio C, Iravani M, Natrajan R, et al. Mixed micropapillary-ductal carcinomas of the breast: A genomic and immunohistochemical analysis of morphologically distinct components. J Pathol. 2009;218:301–315
  37. Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions. Breast Cancer Res. 2003;5:313–319
  38. Stange DE, Radlwimmer B, Schubert F, et al. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res. 2006;12:345–352
  39. Derksen PW, Liu X, Saridin F, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10:437–449
  40. Weigelt B, Geyer FC, Natrajan R, et al. The molecular underpinning of lobular histological growth pattern: A genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol. 2010;220:45–57
  41. Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: Different genetic pathways in ductal and lobular breast cancer?. Breast Cancer Res. 2002;4:5–8
  42. Rakha EA, Pinder SE, Paish EC, et al. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. J Pathol. 2004;203:754–761
  43. Roylance R, Droufakou S, Gorman P, et al. The role of E-cadherin in low-grade ductal breast tumourigenesis. J Pathol. 2003;200:53–58
  44. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression datasets. Proc Natl Acad Sci USA. 2003;100:8418–8423
  45. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22–34
  46. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R4
  47. Jones C, Ford E, Gillet C, et al. Molecular cytogenetic identification of sub-groups of grade III invasive ductal carcinomas with different clinical outcomes. Clin Cancer Res. 2004;10:5988–5997
  48. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: A critical review. J Clin Oncol. 2008;26:2568–2581
  49. Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol. 2003;11:1–8
  50. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10–21
  51. Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology. 2008;52:108–118
  52. Rakha EA, Tan DS, Foulkes WD, et al. Are triple negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res. 2007;9:R80
  53. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921
  54. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116–4124
  55. Weigelt B, Horlings H, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141–150
  56. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15:907–913
  57. Lakhani S, Collins N, Sloane J, et al. Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin Mol Pathol. 1995;48:M74–M78
  58. Lakhani SR, Collins N, Stratton MR, et al. Atypical ductal hyperplasia of the breast: Clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol. 1995;48:611–615
  59. Lu YJ, Osin P, Lakhani SR, et al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res. 1998;58:4721–4727
  60. O'Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998;90:697–703
  61. Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol. 2000;9:14–19
  62. Jones C, Merrett S, Thomas VA, et al. Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast. J Pathol. 2003;199:152–156
  63. Lakhani SR, Slack DN, Hamoudi RA, et al. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest. 1996;74:129–135
  64. Fraser JL, Raza S, Chorny K, et al. Columnar alteration with prominent apical snouts and secretions: A spectrum of changes frequently present in breast biopsies performed for microcalcifications. Am J Surg Pathol. 1998;22:1521–1527
  65. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. Adv Anat Pathol. 2003;10:113–124
  66. Simpson PT, Gale T, Reis-Filho JS, et al. Columnar cell lesions of the breast: The missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol. 2005;29:734–746
  67. Moinfar F, Man YG, Bratthauer GL, et al. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (“clinging ductal carcinoma in situ”): A simulator of normal mammary epithelium. Cancer. 2000;88:2072–2081
  68. Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31:417–426
  69. Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: Further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32:513–523
  70. Deng G, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1996;274:2057–2059
  71. Lakhani SR, Chaggar R, Davies S, et al. Genetic alterations in “normal” luminal and myoepithelial cells of the breast. J Pathol. 1999;189:496–503
  72. Moinfar F, Man YG, Arnould L, et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis. Cancer Res. 2000;60:2562–2566
  73. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 2003;100:5974–5979
  74. Tan DS, Lambros MB, Natrajan R, et al. Getting it right: Designing microarray (and not “microawry”) comparative genomic hybridization studies for cancer research. Lab Invest. 2007;87:737–754
  75. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461:809–813
  76. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–724
  77. Aparicio SA, Huntsman DG. Does massively parallel DNA resequencing signify the end of histopathology as we know it?. J Pathol. 2010;220:307–315
  78. Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009;461:272–276
  79. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: Is there a unifying taxonomy?. Nat Rev Clin Oncol. 2009;6:718–730

PII: S0740-2570(09)00091-4

doi: 10.1053/j.semdp.2009.12.001

Seminars in Diagnostic Pathology
Volume 27, Issue 1 , Pages 91-96 , February 2010

Article Tools